DE60334700D1 - Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren - Google Patents

Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren

Info

Publication number
DE60334700D1
DE60334700D1 DE60334700T DE60334700T DE60334700D1 DE 60334700 D1 DE60334700 D1 DE 60334700D1 DE 60334700 T DE60334700 T DE 60334700T DE 60334700 T DE60334700 T DE 60334700T DE 60334700 D1 DE60334700 D1 DE 60334700D1
Authority
DE
Germany
Prior art keywords
produced
mab
antibody
over
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334700T
Other languages
English (en)
Inventor
Romeuf Christophe De
Arnaud Glacet
Jacky Lirochon
Dominique Bourel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB Biotechnologies SAS
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0211416A external-priority patent/FR2844521B1/fr
Priority claimed from FR0211415A external-priority patent/FR2844520B1/fr
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Application granted granted Critical
Publication of DE60334700D1 publication Critical patent/DE60334700D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60334700T 2002-09-13 2003-09-15 Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren Expired - Lifetime DE60334700D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0211416A FR2844521B1 (fr) 2002-09-13 2002-09-13 Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices
FR0211415A FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie
FR0307067A FR2844513B1 (fr) 2002-09-13 2003-06-12 Anticorps pour adcc et induisant la production de cytokines.
PCT/FR2003/002713 WO2004029092A2 (fr) 2002-09-13 2003-09-15 Anticorps pour adcc et induisant la production de cytokines.

Publications (1)

Publication Number Publication Date
DE60334700D1 true DE60334700D1 (de) 2010-12-09

Family

ID=31950325

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334700T Expired - Lifetime DE60334700D1 (de) 2002-09-13 2003-09-15 Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren

Country Status (9)

Country Link
US (2) US20060127392A1 (de)
EP (1) EP1537147B9 (de)
JP (1) JP2006516951A (de)
AT (1) ATE486094T1 (de)
AU (1) AU2003282160A1 (de)
CA (1) CA2498787A1 (de)
DE (1) DE60334700D1 (de)
FR (1) FR2844513B1 (de)
WO (1) WO2004029092A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1471938A4 (de) * 2002-01-09 2008-03-05 Medarex Inc Menschliche monoklonale antikörper gegen cd30
WO2004087757A2 (en) * 2003-04-03 2004-10-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Antibodies with enhanced ability to immunomodulate cell functions
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
BRPI0516727A (pt) * 2004-10-01 2008-09-16 Medarex Inc métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
CN101128486A (zh) * 2005-02-18 2008-02-20 米德列斯公司 缺乏岩藻糖残基的抗cd30单克隆抗体
US20090214544A1 (en) * 2005-04-25 2009-08-27 Medarex Method of treating cd30 positive lymphomas
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
WO2007084672A2 (en) * 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
EP1933137A1 (de) * 2006-12-15 2008-06-18 Glycode Verfahren zur Untersuchung der Reaktion auf eine Behandlung mit einem monoklonalen Antikörper
WO2008032217A2 (fr) * 2006-09-13 2008-03-20 Glycode Methode d'investigation de la reponse a un traitement par un anticorps monoclonal
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
MX346912B (es) 2009-12-07 2017-04-05 Univ Leland Stanford Junior Metodos para mejorar terapia con anticuerpos antitumor.
US20120294857A1 (en) * 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
WO2014052620A1 (en) * 2012-09-26 2014-04-03 Duke University Adcc-mediating antibodies, combinations and uses thereof
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
MX2015008117A (es) 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
BR112015029395A2 (pt) 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
RU2671089C2 (ru) * 2013-09-16 2018-10-29 Хельмхольтц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
JP6879910B2 (ja) 2014-10-31 2021-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
EP4360714A2 (de) 2016-09-21 2024-05-01 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP4041767A1 (de) 2019-09-26 2022-08-17 StCube & Co. Spezifische antikörper gegen glykosiertes ctla-4 und verfahren zur verwendung davon
KR20220088438A (ko) 2019-10-09 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006119A1 (en) * 1993-08-24 1995-03-02 Scotgen Limited Recombinant humanized anti-human immunodeficiency virus antibody
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU7950400A (en) * 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US20030086929A1 (en) * 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase

Also Published As

Publication number Publication date
JP2006516951A (ja) 2006-07-13
EP1537147B9 (de) 2011-06-29
FR2844513B1 (fr) 2007-08-03
WO2004029092A3 (fr) 2004-09-30
WO2004029092A8 (fr) 2005-04-07
ATE486094T1 (de) 2010-11-15
AU2003282160A1 (en) 2004-04-19
CA2498787A1 (fr) 2004-04-08
US20100145026A1 (en) 2010-06-10
US20060127392A1 (en) 2006-06-15
EP1537147A2 (de) 2005-06-08
FR2844513A1 (fr) 2004-03-19
EP1537147B1 (de) 2010-10-27
WO2004029092A2 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
DE60334700D1 (de) Adcc-vermittelnde antikörper gegen hla-dr, die die produktion von zytokinen induzieren
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
DE60329489D1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
EA200970416A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
DK2180007T4 (da) Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
NZ616992A (en) Anti-ilt7 antibody
WO2003011878A3 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2005016969A3 (en) Cd20-binding polypeptide compositions
EA200870411A1 (ru) Полипептиды с усиленным противовоспалительным и пониженным цитотоксическим свойствами и связанные с ними способы
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
WO2007044756A3 (en) Monoclonal antibodies recognizing human ccr8
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
TW200732350A (en) Methods for generating monovalent IgG
DE60116753D1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
EA200600469A1 (ru) Клетки, продуцирующие композиции антител
DE69925279D1 (de) Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung
WO2003089603A3 (en) Cytokine receptor
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
EP1434799A4 (de) Dna-moleküle und rekombinante dna-moleküle zur herstellung humanisierter monoklonaler antikörper gegen s. mutans
ES2116906B1 (es) Anticuerpo monocional pc2.27 asociado a tumores.
ITTO20020963A1 (it) Linea cellulare di ibridoma e anticorpo monoclonale che riconosce come antigene la proteina umana hmgb1.
TW200500465A (en) Novel humanized anti-vap-1 monoclonal antibody
ATE382639T1 (de) Anti-humane thymidylat-synthase monoklonale antikörper und hybridomazellen zu deren herstellung
AR051887A1 (es) Polipeptidos que unen a br3 y usos de los mismos